iX Biopharma Ltd. (SGX:42C)
0.1170
-0.0010 (-0.85%)
Oct 31, 2025, 5:04 PM SGT
iX Biopharma Revenue
In the fiscal year ending June 30, 2025, iX Biopharma had annual revenue of 7.77M SGD with 30.34% growth. iX Biopharma had revenue of 4.05M in the half year ending June 30, 2025, with 19.76% growth.
Revenue
7.77M
Revenue Growth
+30.34%
P/S Ratio
13.39
Revenue / Employee
221.91K
Employees
35
Market Cap
103.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.77M | 1.81M | 30.34% |
| Jun 30, 2024 | 5.96M | 46.00K | 0.78% |
| Jun 30, 2023 | 5.91M | -8.48M | -58.91% |
| Jun 30, 2022 | 14.39M | 12.65M | 724.64% |
| Jun 30, 2021 | 1.75M | 760.00K | 77.16% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Raffles Medical Group | 765.17M |
| Thomson Medical Group | 455.53M |
| Riverstone Holdings | 324.52M |
| Haw Par Corporation | 253.05M |
| Q & M Dental Group (Singapore) | 180.26M |
| Vicplas International | 120.81M |
| Cordlife Group | 37.64M |